Key result
Bioprosthetic aortic valves show no survival benefit over mechanical valves in dialysis patients.
Why the study?
Whether biological heart valves are inferior to mechanical heart valves in patients with end-stage renal disease undergoing aortic valve replacement was uncertain.
Cohort (n=44)
No
INTRODUCTION: We wanted to answer the question whether biological heart valves are inferior compared to mechanical heart valves in end-stage renal disease (ESRD) patients. METHODS: Between 01/1996 und 12/2006, 44 of 3293 patients undergoing aortic valve replacement (AVR) in a single institution suffered from dialysis-dependent ESRD and underwent a follow-up investigation after 1.9 years (median). Twelve (28.9 %) of these patients received a biological, 32 (71.1 %) of these patients a mechanical aortic valve prosthesis. To evaluate a possible influence of the valve type (biological/mechanical) on survival, uni- and multivariate logistic regression was used. RESULTS: ESRD patients after AVR had a relatively poor short-term (30-day mortality: 22.7 %) and long-term survival (median survival time: 24.7 months; 95 % CI: 0.2-47.7 months), irrespective of the type of heart valve prosthesis (hazard ratio for mortality depending on heart valve type in dialysis patients: 1.31, P = 0.400). Dialysis-dependent patients were not reoperated due to valve-related reasons. CONCLUSIONS: The long-term survival of dialysis-dependent patients after AVR is low (5-year survival: 29.5 %) irrespective of the type of heart valve prosthesis. Therefore, the use of biological AVR is not contraindicated in this group of patients.
No takes yet. Share an insight, caveat, or question.
Böning et al. (2011) conducted a cohort in Dialysis-dependent end-stage renal disease undergoing aortic valve replacement (n=44). Biological aortic valve prosthesis vs. Mechanical aortic valve prosthesis was evaluated on Mortality (HR 1.31, p=0.400). Biological vs mechanical aortic valve prosthesis in dialysis patients showed no significant difference in mortality (HR 1.31, P=0.400), with overall 5-year survival of 29.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: